Lynch Brian Joseph 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Jan 25, 2024
Insider Transaction Report
Form 4
Lynch Brian Joseph
SVP and General Counsel
Transactions
- Award
Market Stock Unit
2024-01-23+3,639→ 3,639 total→ Common Stock (3,639 underlying) - Award
Common Stock
2024-01-23+3,639→ 17,691 total - Award
Stock Option (Right to Buy)
2024-01-23+5,483→ 5,483 totalExercise: $229.00Exp: 2031-01-23→ Common Stock (5,483 underlying)
Holdings
- 530(indirect: By IRA)
Common Stock
Footnotes (3)
- [F1]Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
- [F2]The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
- [F3]Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.